FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to biotechnology. What is presented is a composition of antibodies possessing an IGF-IR binding capacity and prepared by culturing a CHO DSM ACC 2795 cell line with an amount of fucose residues in a sugar chain of the antibodies making at least 99%. What is also disclosed is a pharmaceutical composition for tumour growth inhibition and a method for preparing the above pharmaceutical composition by mixing a composition of the antibodies according to the invention with a pharmaceutically acceptable carrier.
EFFECT: composition of the antibodies possesses a low antibody-dependent cell-mediated cytotoxicity (ADCC) and can be used in the therapy of IGF-IR associated diseases.
5 cl, 1 dwg, 4 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS | 2010 |
|
RU2604189C2 |
| BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEINS | 2010 |
|
RU2573914C2 |
| BIVALENT BISPECIFIC ANTIBODIES | 2008 |
|
RU2547615C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
| BINDING PROTEINS SPECIFIC TO INSULIN-LIKE GROWTH FACTORS, AND USING THEM | 2013 |
|
RU2549703C2 |
| IL-13 RECEPTOR ALPHA 1 ANTIBODIES AND THEIR APPLICATION | 2006 |
|
RU2413736C2 |
| HUMANISED ANTIBODIES TO CDCP1 | 2010 |
|
RU2571207C2 |
| POLYSPECIFIC ANTIBODIES CONTAINING ANTIBODY OF FULL LENGTH AND ONE-CHAIN FRAGMENTS FAB | 2010 |
|
RU2598248C2 |
| BIVALENT BISPECIFIC ANTIBODIES | 2008 |
|
RU2587616C2 |
